We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Rechargeable Neuromodulation Implant Treats Bowel Dysfunction

By HospiMedica International staff writers
Posted on 02 Oct 2019
A novel implantable sacral neuromodulation (SNM) device is designed to aid patients suffering from fecal incontinence, overactive bladder (OAB), and urinary retention.

The Axonics Modulation Technologies (Irvine, CA, USA) rechargeable SNM (r-SNM) system offers a long-lived miniaturized neurostimulator, approximately the size of a USB stick that can last for up to 15 years in the body. More...
Features include a patented tined lead and user-friendly accessories. Key features include a wireless charging system optimized for infrequent charging, a small easy-to-use patient remote control, and an intuitive clinician programmer that facilitates lead placement and stimulation programming.

The system works by imitating a signal sent via the central nervous system (CNS) when the nerves in the sacral area and the brain no longer communicate effectively, thus leading to a bowel and/or bladder disorder. By stimulating the sacral nerve, a neurological signal is sent that manipulates a contraction within the pelvic floor. Over time, these contractions rebuild the strength of the organs and muscles, alleviating or eliminating symptoms of OAB and of the urinary or fecal disorder.

“Axonics has successfully developed a unique product to deliver SNM therapy that we believe will greatly improve the patient and clinician experience. It also features quick, safe charging capability and a patient-friendly wireless remote control,” said Raymond Cohen, CEO of Axonics. “We believe the number of patients seeking SNM treatment will expand dramatically over the next few years given our fuss-free, long-lived, full body MRI-compatible device.”

OAB affects more than 37 million people in the United States alone, with a significant impact on the quality of life of suffers by affecting a person’s social activities, exercise regimen, and by causing disruptive nighttime voiding. Despite this, only 33% of those suffering seek treatment, and as many as 70% stop using their medication within six months due to intolerable side effects or unsatisfying results.

Related Links:
Axonics Modulation Technologies


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.